ImmunoMet begins Phase I cancer trial of OXPHOS Inhibitor IM156

US-based biotechnology firm ImmunoMet Therapeutics has started its Phase I clinical trial for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor to treat patients with solid tumours.    
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news